Literature DB >> 32284732

A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab.

A Pefanis1, D S Williams1, H Skrzypek2, A Fung2, K Paizis1,2.   

Abstract

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are rare small vessel vasculitides of unknown cause. The pathogenic role of MPO-ANCA in the vasculitides has been supported using various animal models, with B-cells playing a role in the disease pathogenesis. Pregnancy in the presence of an autoimmune disease such as vasculitis is often associated with significant morbidity. Little is known about the outcomes when women present with de novo vasculitis during pregnancy, and the appropriate management of such presentations is unclear. We describe a case of a 33-year-old female presenting in her second pregnancy with new onset ANCA vasculitis at 12 weeks' gestation. She was successfully treated with prednisolone and rituximab, and delivered a healthy 2.8 kg boy at 36 weeks' gestation with no clinical manifestations of vasculitis or neutropenia in the neonate.
© The Author(s) 2018.

Entities:  

Keywords:  Antineutrophil cytoplasm antibody vasculitis; pregnancy; rituximab

Year:  2018        PMID: 32284732      PMCID: PMC7133104          DOI: 10.1177/1753495X18780853

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  22 in total

1.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

2.  Pregnancy outcomes after maternal exposure to rituximab.

Authors:  Eliza F Chakravarty; Elaine R Murray; Ariella Kelman; Pamela Farmer
Journal:  Blood       Date:  2010-11-23       Impact factor: 22.113

Review 3.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 4.  Treatment with biologics of pregnant patients with rheumatic diseases.

Authors:  Monika Ostensen; Frauke Förger
Journal:  Curr Opin Rheumatol       Date:  2011-05       Impact factor: 5.006

5.  Wegener's granulomatosis arising in pregnancy.

Authors:  C A Milford; M Bellini
Journal:  J Laryngol Otol       Date:  1986-04       Impact factor: 1.469

6.  Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs.

Authors:  David J Schlieben; Stephen M Korbet; Robert E Kimura; Melvin M Schwartz; Edmund J Lewis
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

7.  Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies.

Authors:  Rolando Cimaz; Dawn L Spence; Lisa Hornberger; Earl D Silverman
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

8.  Wegener's granulomatosis in pregnancy: a novel approach to management.

Authors:  Rosemary Masterson; Rebecca Pellicano; Karl Bleasel; Lawrence P McMahon
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

9.  Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.

Authors:  Carsten Schröder; Agnes M Azimzadeh; Guosheng Wu; James O Price; James B Atkinson; Richard N Pierson
Journal:  Transpl Immunol       Date:  2003 Oct-Nov       Impact factor: 1.708

Review 10.  IgG placental transfer in healthy and pathological pregnancies.

Authors:  Patricia Palmeira; Camila Quinello; Ana Lúcia Silveira-Lessa; Cláudia Augusta Zago; Magda Carneiro-Sampaio
Journal:  Clin Dev Immunol       Date:  2011-10-01
View more
  1 in total

Review 1.  Pregnancy Outcomes in Systemic Vasculitides.

Authors:  Carolyn Ross; Rohan D'Souza; Christian Pagnoux
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.